Braidwell LP Sells 162,894 Shares of Nuvalent, Inc.

Institutional investor reduces stake in biotech company

Mar. 15, 2026 at 8:57am

Got story updates? Submit your updates here. ›

Braidwell LP, an institutional investor, decreased its stake in Nuvalent, Inc. (NASDAQ:NUVL) by 13.9% in the third quarter, according to a recent SEC filing. The firm now owns 1,012,982 shares of the company's stock, making it Nuvalent's 11th largest shareholder.

Why it matters

Institutional investors' buying and selling activity can provide insights into market sentiment and the outlook for a company. Braidwell LP's decision to reduce its position in Nuvalent may signal concerns about the biotech firm's prospects or a shift in the investor's overall portfolio strategy.

The details

According to the filing, Braidwell LP sold 162,894 shares of Nuvalent, reducing its total stake to 1,012,982 shares. The firm now owns 1.39% of Nuvalent's outstanding shares, worth approximately $87.6 million as of the most recent quarter. Other institutional investors, including Ameriprise Financial and Wellington Management Group, have also made changes to their Nuvalent holdings in recent quarters.

  • Braidwell LP's stake reduction occurred in the third quarter of the year.

The players

Braidwell LP

An institutional investor that owns a significant stake in Nuvalent, Inc.

Nuvalent, Inc.

A clinical-stage precision oncology company focused on developing targeted therapies for patients with genetically defined cancers.

Ameriprise Financial Inc.

Another institutional investor that has made changes to its Nuvalent holdings in recent quarters.

Wellington Management Group LLP

An institutional investor that has also adjusted its position in Nuvalent in recent quarters.

Got photos? Submit your photos here. ›

The takeaway

Braidwell LP's decision to reduce its stake in Nuvalent may signal broader market concerns about the biotech company's prospects, though the reasons behind the move are not entirely clear. Investors will likely continue to monitor institutional activity and analyst sentiment around Nuvalent as the company progresses its pipeline of targeted cancer therapies.